We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing

By LabMedica International staff writers
Posted on 03 Nov 2020
Print article
Image: New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing (Photo courtesy of Wits University)
Image: New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing (Photo courtesy of Wits University)
A team of researchers have developed a unique “control standard” that improves accuracy and safety of COVID-19 testing by using biomimicry as a safer alternative to incorporating the actual SARS-COV-2 virus.

Researchers at the Centre for Biomedical Tuberculosis Research at Wits University (Johannesburg, South Africa) have used the biomimicry technique to engineer a control organism that mimics the genetic material of the virus, when used in diagnostic tests kits. If the tests work correctly, the genetically modified organism is identified as being SARS-CoV-2. The control is a safe, non-pathogenic (non-disease causing), and stable. It can be rapidly deployed in a range of settings - from central laboratories to clinics. In contrast, viral-based controls require specialist shipping and handling procedures, and the need for highly-skilled staff and infrastructure.

Accuracy of testing controls is central to the deployment of any successful diagnostic test. The new control aims to fill the gap in the verification of COVID-19 tests obtained via molecular diagnosis tools, and reduce the risks and complications of using the live virus.

“The virus continues to spread viciously across countries, with infections again rising rapidly across Europe and North America,” said Professor Bavesh Kanawho headed the Wits team. “In order for governments to halt its spread, reliable tools with verifiable results are of utmost importance. Without appropriate controls to report whether tests are delivering the correct result diagnosing and effectively managing COVID-19 will be very difficult, if not impossible.”

Related Links:
Wits University

Gold Supplier
SARS-CoV-2 Ag Controls
Lumipulse® SARS-CoV-2 Ag Controls
New
SARS-CoV-2 Antibody Test
Finecare 2019-nCoV Antibody Test
New
Silver Supplier
Disposable Viral Preservation Tube
Disposable Viral Preservation Tube
New
Gold Supplier
COVID-19 Nucleic Acid Releaser (For PCR)
Nucleic Acid Releaser (For PCR)

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.